Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate
暂无分享,去创建一个
R. Baric | A. García-Sastre | P. Palese | A. Schäfer | F. Krammer | S. Leist | K. Dinnon | F. Amanat | Weina Sun | Yonghong Liu | S. McCroskery | S. Slamanig | Justine Oliva | A. Schaefer | J. Oliva | S. Mccroskery | Stephen McCroskery
[1] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[2] R. Albrecht,et al. An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening , 2020, Current protocols in microbiology.
[3] J. Mascola,et al. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness , 2020, bioRxiv.
[4] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[5] A. Basu,et al. Faculty Opinions recommendation of Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[6] C. Poh,et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients , 2020, Nature Communications.
[7] Y. Hu,et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.
[8] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[9] C. Cunningham-Rundles,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.
[10] Lisa E. Gralinski,et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures , 2020, bioRxiv.
[11] Xiangxi Wang,et al. Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.
[12] Velizar Shivarov,et al. Potential SARS-CoV-2 Preimmune IgM Epitopes , 2020, Frontiers in Immunology.
[13] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[14] I. Wilson,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[15] F. Krammer,et al. SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.
[16] Nicholas C. Wu,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[17] Arturo Casadevall,et al. The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.
[18] R. Scheuermann,et al. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.
[19] Matthew R. McKay,et al. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies , 2020, bioRxiv.
[20] D. Zamarin,et al. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. , 2019, Methods in molecular biology.
[21] P. Palese,et al. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma , 2019, EBioMedicine.
[22] Z. Bu,et al. Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels , 2017, Journal of Integrative Agriculture.
[23] V. Schirrmacher. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! , 2016, Biomedicines.
[24] P. Palese,et al. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. , 2012, Future microbiology.
[25] A. García-Sastre,et al. Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy , 2008, Molecular Therapy.
[26] B. Murphy,et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens , 2007, Proceedings of the National Academy of Sciences.
[27] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[28] A. García-Sastre,et al. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Gomori,et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] Jianrong Li,et al. Decreased Dependence on Receptor Recognition for the Fusion Promotion Activity of L289A-Mutated Newcastle Disease Virus Fusion Protein Correlates with a Monoclonal Antibody-Detected Conformational Change , 2005, Journal of Virology.
[31] J. Marshall,et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] E. Mundt,et al. Generation of recombinant lentogenic Newcastle disease virus from cDNA. , 1999, The Journal of general virology.
[33] B. Peeters,et al. Rescue of Newcastle Disease Virus from Cloned cDNA: Evidence that Cleavability of the Fusion Protein Is a Major Determinant for Virulence , 1999, Journal of Virology.